To: Heather Bresch, CEO of Mylan

Stop Immoral Price Gouging for Life-Saving EpiPen

Stop price-gouging the millions of people who need an EpiPen to save their lives if they have a severe allergic reaction.

Why is this important?

*UPDATE: The company’s “solution” in the face of overwhelming public outcry is to offer more coupons. But it has not lowered the price ONE CENT. So keep the pressure up!*

Millions of children and adults in the U.S. are at risk of fatal allergic reactions from common occurrences like getting stung by a bee or accidentally consuming peanuts.

A pocket-sized medical device called an EpiPen can be a literal life-saver for these folks.

But Mylan — the multinational pharmaceutical company that makes the EpiPen — has been steadily jacking up the price.

- In 2007, the wholesale price on an EpiPen in the U.S. was $57.

- Today, just nine years later, it’s over $300.

- Even though each EpiPen contains only a few dollars’ worth of medicine.

- Even though a two-pack is just $85 in France.

- And even though Mylan, which has a near monopoly in the U.S., has seen its profits from the EpiPen alone skyrocket to $1.2 billion a year.

Now, many people who could actually die without an EpiPen can’t afford one!

Tell Mylan CEO Heather Bresch to immediately reduce the price of this life-and-death treatment that so many people depend on.